Ascendis Pharma (NASDAQ: ASND) reported Q2 EPS of (EUR1.91), EUR0.55 worse than the analyst estimate of (EUR1.36). Revenue for the quarter came in at EUR36 million versus the consensus estimate of EUR83.7 million.

The company sees Skytrofa revenue EU220 million to EU240 million, down from the prior range of EU320 million to EU340 million, vs. estimated EU350.7 million

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.